most Bifidobacterium and Lactobacillus strains that colonize the mammalian intestines reveal BSH activity, and in general bifidobacteria have higher BSH activity than lactobacilli [8] . Additionally, several strains of commercially available probiotic bacteria also exhibit BSH activity [9] . Therefore, alteration of the intestinal microflora by ingesting probiotics and/or a selection of probiotics possessing BSH activity may promote the hydrolysis of conjugated bile acids in the intestines. As unconjugated bile acids are less soluble and less efficiently reabsorbed from the intestinal lumen, a majority of these acids are excreted in the feces [7, 10] . Thus, probiotics may facilitate bile acid excretion, increase de novo synthesis of bile acids from cholesterol, and cause lower serum cholesterol levels.
Conversely, several reviews have described how microbial BSH activity could potentially be detrimental to the human host [11, 12] . After deconjugation by BSH, the unconjugated bile acids (but not conjugated bile acids) may be converted to secondary bile acids through the microbial bile acid 7α-dehydroxylation pathway [13] . Some researchers assume that nearly all bile acids that escape the enterohepatic circulation are converted to secondary bile acids before excretion [14] .
Several studies have reported that secondary bile acids cause DNA damage and are linked to colon carcinogenesis [14] [15] [16] . Moreover, secondary bile acids have been found in high concentrations in the fecal water of colon cancer patients [17] . Accordingly, the effects of probiotic intake on bile acid metabolism need to be explored for safety measures. Thus, in order to further understand the influence of probiotic intake on fecal bile acid levels, we analyzed the bile acid levels and microbiota in the human fecal samples after probiotic supplementation.
METHODS

Patients
Two patients hospitalized for dyslipidemia and schizophrenia (Subjects A and B) were enrolled in this study. The baseline characteristics of the subjects are presented in Table 1 . Both subjects received an atypical antipsychotic drug and an intestinal drug (magnesium oxide), and Subject B received medication that increases the peristaltic colon activity in addition to a cholesterollowering medication. Both subjects gave their informed consent to participate in this study, and the ethics committee of Yamagata Prefectural Yonezawa University of Nutrition Sciences approved this study. The study protocol conformed to the tenets of the Declaration of Helsinki.
Study design
We used supplement sachets of powdered Lactobacillus rhamnosus GG (LGG) containing 1.4 × 4 weeks, and further avoided the supplement for the subsequent 4 weeks. Fecal samples were collected at baseline and after 4 weeks (supplementation) and 8 weeks (no supplementation). Their diet and medication remained unaltered, and the subjects were instructed to avoid consumption of foods or supplements comprising other lactic acid bacteria or bifidobacteria during the study period. Furthermore, their defecation frequency remained the same during the study period. BMI, body mass index; To-Cho, total cholesterol; TG, triglyceride.
Analysis
Fecal samples were collected three times (at baseline, 4 weeks, and 8 weeks) and stored at −80 °C until further analysis. Fecal microbiota was analyzed by targeting the bacterial 16S rRNA genes using the terminal restriction fragment length polymorphism (T-RFLP) [18] [19] [20] [21] . The fecal concentrations of conjugated bile acids (glycocholic acid, taurocholic acid, glycochenodeoxycholic acid, and taurochenodeoxycholic acid), unconjugated bile acids (cholic acid and chenodeoxycholic acid), and secondary bile acids (deoxycholic acid and lithocholic acid) were measured using liquid chromatography/quadrupole time-of-flight mass spectrometry (LC-QTOF/MS). All samples were analyzed by Techno Suruga Laboratory Co., Ltd. (Shizuoka, Japan).
RESULTS
Alterations in the intestinal microflora may affect the bile acid deconjugation, because most
Bifidobacterium and Lactobacillus strains that colonize the intestines exhibit BSH activity [8] . The relative abundance of Bifidobacterium and Lactobacillales in the feces was assessed by T-RFLP analysis (Figure 1) . The relative abundance of Bifidobacterium, including strains that report high BSH activity [8] , increased after probiotic supplementation in Subject A (30%-49%), and then decreased after the nonsupplementation period (to 35%). Interestingly, the relative abundance of Bifidobacterium in Subject B remained relatively constant throughout the study period.
To examine the influence of probiotic intake on fecal bile acid levels, we analyzed these levels in fecal samples collected at baseline and after the supplementation and nonsupplementation periods ( Figure 2 ). The fecal unconjugated bile acid and secondary bile acid levels in Subject A increased 5-fold (0.36-1.79 µmol/g) and 8.8-fold (1.82-16.19 µmol/g) after supplementation, respectively, and these levels decreased after the nonsupplementation period. Alternatively, the fecal bile acid levels in Subject B remained relatively constant throughout the study period, and no fecal unconjugated bile acids were detected. 
